Table 1.
Baseline characteristics of all included patients, patients with a successful organoid culture and subsequent drug screen, and patients that received an organoid-informed treatment, in comparison with the clinical characteristics in the pilot set. Information not available for a = 7, b = 9, c = 4, d = 6, e = 12, f = 1. For 7 patients, no tissue for organoid culture was retrieved (g)
| All patients |
Drug screen |
Treated patients |
Pilot set |
|
|---|---|---|---|---|
| n = 62 | n = 25 | n = 6 | n = 16 | |
| Median age (range), years | 59.5 (26-78) | 57 (30-73) | 57 (51-65) | N/A |
| Male : female n : n | 35 : 26 | 11 : 14 | 3 : 3 | N/A |
| WHO, n (%) | a | |||
| 0 | 34 (61%) | 14 (56%) | 3 (50%) | N/A |
| 1 | 20 (36%) | 10 (40%) | 3 (50%) | |
| 2 | 1 (2%) | 1 (4%) | 0 | |
| Localization of primary, n (%) | ||||
| Colon | 34 (55%) | 16 (64%) | 3 (50%) | 10 (63%) |
| Rectum | 14 (23%) | 5 (20%) | 3 (50%) | 2 (13%) |
| Rectosigmoid | 2 (3%) | 2 (8%) | 0 | 1 (6%) |
| Colorectal NOS | 12 (19%) | 2 (8%) | 0 | 3 (19%) |
| Differentiation, n (%) | c | d | ||
| Well/moderately | 38 (72%) | 14 (67%) | 5 (83%) | 8 (80%) |
| Poorly | 12 (23%) | 6 (29%) | 1 (17%) | 1 (10%) |
| Mucinous | 3 (6%) | 1 (5%) | 0 | 1 (10%) |
| Undifferentiated | 0 | 0 | 0 | 0 |
| Biopsied lesion, n (%) | g | |||
| Liver | 28 (51%) | 18 (72%) | 3 (50%) | 6 (38%) |
| Primary | 0 | 0 | 0 | 7 (44%) |
| Lymph node | 11 (20%) | 5 (20%) | 2 (33%) | 1 (6%) |
| Peritoneum | 5 (9%) | 1 (4%) | 0 | 0 |
| Other | 12 (22%) | 1 (4%) | 1 (17%) | 1 (6%) |
| Microsatellite status, n (%) | e | f | ||
| MSI | 1 (2%) | 1 (4%) | 0 | 2 (13%) |
| MSS | 49 (98%) | 24 (96%) | 6 (100%) | 13 (87%) |
| Prior lines of (chemo)therapy | ||||
| 0 | 20 (32%) | 2 (8%) | 0 | 12 (75%) |
| 1 | 25 (40%) | 11 (44%) | 2 (33%) | 2 (13%) |
| ≥2 | 17 (27%) | 12 (48%) | 4 (67%) | 2 (13%) |